Ongoing Disclosure Notices - Options, PSRs, Ordinary Shares

Ongoing Disclosure Notice
Disclosure of Directors and Senior Managers Relevant Interests
Sections 297(2) and 298(2), Financial Markets Conduct Act 2013
To NZX Limited; and
Name of listed issuer:
Fisher & Paykel Healthcare Corporation Limited
Date this disclosure made:
25 September 2026
Date of last disclosure:
18 September 2026
Director or senior manager giving disclosure
Full name(s):
Justin Peter Callahan
Name of listed issuer:
Fisher & Paykel Healthcare Corporation Limited
Name of related body corporate (if applicable):
Position held in listed issuer:
Vice President - Sales & Marketing
Summary of acquisition or disposal of relevant interest (excluding specified derivatives)
Class of affected quoted financial products: Ordinary Shares
Nature of the affected relevant interest(s):
Beneficial Interest
For that relevant interest-
Number held in class before acquisition or disposal:258,930 Ordinary Shares
Number held in class after acquisition or disposal:221,009 Ordinary Shares
Current registered holder(s):
Justin Peter Callahan
Registered holder(s) once transfers are registered:
Justin Peter Callahan
Summary of acquisition or disposal of specified derivatives relevant interest (if applicable)
Type of affected derivative:
Class of underlying financial products:
Details of affected derivative-
The notional value of the derivative (if any) or the notional amount of underlying
financial products (if any):
A statement as to whether the derivative is cash settled or physically settled:
Maturity date of the derivative (if any):
Expiry date of the derivative(if any):
The price specified in the terms of the derivative (if any):
Any other details needed to understand how the amount of the consideration payable
under the derivative or the value of the derivative is affected by the value of the
underlying financial products:
For that derivative,-
Parties to the derivative:
If the director or senior manager is not a party to the derivative, the nature of the
relevant interest in the derivative:
Details of transactions giving rise to acquisition or disposal
Total number of transactions to which notice relates:
One
Details of transactions requiring disclosure-
Date of transaction:18 September 2026
Nature of transaction: Sale of Ordinary Shares
Name of any other party or parties to the transaction (if known):
The consideration, expressed in New Zealand dollars, paid or received for the
acquisition or disposal. If the consideration was not in cash and cannot be readily by
converted into a cash value, describe the consideration:
$43.41 per Ordinary Share
Number of financial products to which the transaction related:
Sale of 37,921 Ordinary Shares
If the issuer has a financial products trading policy that prohibits directors or senior
managers from trading during any period without written clearance (a closed period)
include the following details—

Whether relevant interests were acquired or disposed of during a closed period:
Whether prior written clearance was provided to allow the acquisition or disposal to
proceed during the closed period:
Date of the prior written clearance (if any):
Summary of other relevant interests after acquisition or disposal:
Class of quoted financial products:
a) Options to acquire Ordinary Shares
b) Performance Share Rights
Nature of relevant interest:
Beneficial Interest
For that relevant interest,-
Number held in class:
a) 74,853 Options to acquire Ordinary Shares
b) 76,839 Performance Share Rights
Current registered holder(s):Justin Peter Callahan
For a derivative relevant interest,-
Type of derivative:
Details of derivative,-
The notional value of the derivative (if any) or the notional amount of underlying
financial products (if any):
A statement as to whether the derivative is cash settled or physically settled:
Maturity date of the derivative (if any):
Expiry date of the derivative (if any):
The price's specified terms (if any):
Any other details needed to understand how the amount of the consideration payable
under the derivative or the value of the derivative is affected by the value of the
underlying financial products:
For that derivative relevant interest,-
Parties to the derivative:
If the director or senior manager is not a party to the derivative, the nature of the
relevant interest in the derivative:
Certification
I, certify that, to the best of my knowledge and belief, the information contained in this
disclosure is correct and that I am duly authorised to make this disclosure by all
persons for whom it is made.
Signature of director or officer:
Date of signature:
or
Signature of person authorised to sign on behalf of director or officer:
Date of signature:25 September 2026
Name and title of authorised person:
Raelene Leonard,
General Counsel & Company Secretary

---

Ongoing Disclosure Notice
Disclosure of Directors and Senior Managers Relevant Interests
Sections 297(2) and 298(2), Financial Markets Conduct Act 2013
To NZX Limited; and
Name of listed issuer: Fisher & Paykel Healthcare Corporation Limited
Date this disclosure made:25 September 2026
Date of last disclosure: 9 September 2026
Director or senior manager giving disclosure
Full name(s):Lewis George Gradon
Name of listed issuer:Fisher & Paykel Healthcare Corporation Limited
Name of related body corporate (if applicable):
Position held in listed issuer:Chief Executive Officer
Summary of acquisition or disposal of relevant interest (excluding specified derivatives)
Class of affected quoted financial products:
a) Performance Share Rights
b) Options to Acquire Ordinary Shares
c) Ordinary Shares
Nature of the affected relevant interest(s):Beneficial Interest
For that relevant interest-
Number held in class before acquisition or disposal:
a) 208,815 Performance Share Rights
b) 198,657 Options to acquire Ordinary Shares
c) 558,934 Ordinary Shares
Number held in class after acquisition or disposal:
a) 159,565 Performance Share Rights
b) 85,480 Options to acquire Ordinary Shares
c) 565,961 Ordinary Shares
Current registered holder(s):
a) Lewis George Gradon
b) Lewis George Gradon
c) Lewis George Gradon; Gradon Family Trust
Registered holder(s) once transfers are registered:
a) Lewis George Gradon
b) Lewis George Gradon
c) Lewis George Gradon; Gradon Family Trust
Summary of acquisition or disposal of specified derivatives relevant interest (if applicable)
Type of affected derivative:
Class of underlying financial products:
Details of affected derivative-
The notional value of the derivative (if any) or the notional amount of underlying
financial products (if any):
A statement as to whether the derivative is cash settled or physically settled:
Maturity date of the derivative (if any):
Expiry date of the derivative (if any):
The price specified in the terms of the derivative (if any):
Any other details needed to understand how the amount of the consideration payable
under the derivative or the value of the derivative is affected by the value of the
underlying financial products:
For that derivative,-
Parties to the derivative:
If the director or senior manager is not a party to the derivative, the nature of the
relevant interest in the derivative:
Details of transactions giving rise to acquisition or disposal
Total number of transactions to which notice relates:
Five
Details of transactions requiring disclosure-
Date of transaction:
a) 21 September 2026
b) 21 September 2026
c) 23 September 2026
d) 23 September 2026
e) 24 September 2026

Nature of transaction:
a) Exercise of Performance Share Rights and
Issue of Ordinary Shares
b) Sale of Ordinary Shares
c) Exercise and cancellation of Options and Issue
of Ordinary Shares
d) Sale of Ordinary Shares
e) Sale of Ordinary Shares
Name of any other party or parties to the transaction (if known):
The consideration, expressed in New Zealand dollars, paid or received for the
acquisition or disposal. If the consideration was not in cash and cannot be readily by
converted into a cash value, describe the consideration:
a) Nil
b) $44.5340 per Ordinary Share
c) Exercise price of $21.96 per Ordinary Share
d) $45.0368 per Ordinary Share
e) $44.8037 per Ordinary Share
Number of financial products to which the transaction related:
a) Exercise of 49,250 Performance Share Rights
and Issue of 49,250 Ordinary Shares
b) Sale of 50,000 Ordinary Shares
c) Exercise of 113,177 Options and Issue of
57,777 Ordinary Shares
d) Sale of 18,138 Ordinary Shares
e) Sale of 31,862 Ordinary Shares
If the issuer has a financial products trading policy that prohibits directors or senior
managers from trading during any period without written clearance (a closed period)
include the following details—
Whether relevant interests were acquired or disposed of during a closed period:
Whether prior written clearance was provided to allow the acquisition or disposal to
proceed during the closed period:
Date of the prior written clearance (if any):
Summary of other relevant interests after acquisition or disposal:
Class of quoted financial products:
Nature of relevant interest:
For that relevant interest,-
Number held in class:
Current registered holder(s):
For a derivative relevant interest,-
Type of derivative:
Details of derivative,-
The notional value of the derivative (if any) or the notional amount of underlying
financial products (if any):
A statement as to whether the derivative is cash settled or physically settled:
Maturity date of the derivative (if any):
Expiry date of the derivative (if any):
The price's specified terms (if any):
Any other details needed to understand how the amount of the consideration payable
under the derivative or the value of the derivative is affected by the value of the
underlying financial products:
For that derivative relevant interest,-
Parties to the derivative:
If the director or senior manager is not a party to the derivative, the nature of the
relevant interest in the derivative:
Certification
I, certify that, to the best of my knowledge and belief, the information contained in this
disclosure is correct and that I am duly authorised to make this disclosure by all
persons for whom it is made.
Signature of director or officer:
Date of signature:
or
Signature of person authorised to sign on behalf of director or officer:
Date of signature:25 September 2026
Name and title of authorised person:
Raelene Leonard,
General Counsel & Company Secretary

---

Ongoing Disclosure Notice
Disclosure of Directors and Senior Managers Relevant Interests
Sections 297(2) and 298(2), Financial Markets Conduct Act 2013
To NZX Limited; and
Name of listed issuer:
Fisher & Paykel Healthcare Corporation Limited
Date this disclosure made:
25 September 2026
Date of last disclosure:
1 October 2024
Director or senior manager giving disclosure
Full name(s):
Andrew Mark Cross
Name of listed issuer:
Fisher & Paykel Healthcare Corporation Limited
Name of related body corporate (if applicable):
Position held in listed issuer:
Director
Summary of acquisition or disposal of relevant interest (excluding specified derivatives)
Class of affected quoted financial products: Ordinary Shares
Nature of the affected relevant interest(s):
Beneficial Interest
For that relevant interest-
Number held in class before acquisition or disposal:4,000 Ordinary Shares
Number held in class after acquisition or disposal:9,000 Ordinary Shares
Current registered holder(s):
Alpha Investment Partners Limited as corporate
trustee for Alpha Investment Trust
Registered holder(s) once transfers are registered:
Alpha Investment Partners Limited as corporate
trustee for Alpha Investment Trust
Summary of acquisition or disposal of specified derivatives relevant interest (if applicable)
Type of affected derivative:
Class of underlying financial products:
Details of affected derivative-
The notional value of the derivative (if any) or the notional amount of underlying
financial products (if any):
A statement as to whether the derivative is cash settled or physically settled:
Maturity date of the derivative (if any):
Expiry date of the derivative(if any):
The price specified in the terms of the derivative (if any):
Any other details needed to understand how the amount of the consideration payable
under the derivative or the value of the derivative is affected by the value of the
underlying financial products:
For that derivative,-
Parties to the derivative:
If the director or senior manager is not a party to the derivative, the nature of the
relevant interest in the derivative:
Details of transactions giving rise to acquisition or disposal
Total number of transactions to which notice relates:
One
Details of transactions requiring disclosure-
Date of transaction:22 September 2026
Nature of transaction: Purchase of Ordinary Shares
Name of any other party or parties to the transaction (if known):
The consideration, expressed in New Zealand dollars, paid or received for the
acquisition or disposal. If the consideration was not in cash and cannot be readily by
converted into a cash value, describe the consideration:
$44.86 per Ordinary Share
Number of financial products to which the transaction related:
Purchase of 5,000 Ordinary Shares

If the issuer has a financial products trading policy that prohibits directors or senior
managers from trading during any period without written clearance (a closed period)
include the following details—
Whether relevant interests were acquired or disposed of during a closed period:
Whether prior written clearance was provided to allow the acquisition or disposal to
proceed during the closed period:
Date of the prior written clearance (if any):
Summary of other relevant interests after acquisition or disposal:
Class of quoted financial products:
Nature of relevant interest:
For that relevant interest,-
Number held in class:
Current registered holder(s):
For a derivative relevant interest,-
Type of derivative:
Details of derivative,-
The notional value of the derivative (if any) or the notional amount of underlying
financial products (if any):
A statement as to whether the derivative is cash settled or physically settled:
Maturity date of the derivative (if any):
Expiry date of the derivative (if any):
The price's specified terms (if any):
Any other details needed to understand how the amount of the consideration payable
under the derivative or the value of the derivative is affected by the value of the
underlying financial products:
For that derivative relevant interest,-
Parties to the derivative:
If the director or senior manager is not a party to the derivative, the nature of the
relevant interest in the derivative:
Certification
I, certify that, to the best of my knowledge and belief, the information contained in this
disclosure is correct and that I am duly authorised to make this disclosure by all
persons for whom it is made.
Signature of director or officer:
Date of signature:
or
Signature of person authorised to sign on behalf of director or officer:
Date of signature:25 September 2026
Name and title of authorised person:
Raelene Leonard,
General Counsel & Company Secretary